<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02574338</url>
  </required_header>
  <id_info>
    <org_study_id>MSFC-2015-CT</org_study_id>
    <nct_id>NCT02574338</nct_id>
  </id_info>
  <brief_title>Cervical Ripening: A Comparison Between Intravaginal Misoprostol Tablet and Intracervical Foley's Catheter in a Low Resource Setting</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nwali Matthew Igwe</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal Teaching Hospital Abakaliki</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the effectiveness and safety of Foley's catheter and
      misoprostol in cervical ripening.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized clinical which will be made up of two arms or groups. The first arm or
      group - 1 will have cervical ripening with intracervical extraamniotic Foley's catheter while
      group - 2 will have cervical ripening with intravaginal misoprostol. The parturients will be
      randomly selected by simple lottery and recruited into the two arms of the study. Each
      parturient will pick by simple lucky dip from a pool of folded papers with inscription group
      1 or group 2 in a bag in a double blinded manner and will be recruited into the group picked
      among the two arms of the study. The Bishop's score of the cervix will be accurately
      determined and documented before cervical ripening. Bishop's score of ≥6 will be considered
      ripe.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2015</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bishop Score of 6 or more</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Cervical Ripening</condition>
  <arm_group>
    <arm_group_label>group - 1 Foley's Catheter</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>will have cervical ripening with intracervical extraamniotic Foley's catheter for 24 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group - 2 Prostaglandin E1 Analogue</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>will have cervical ripening with intravaginal misoprostol inserted into the posterior fornix every six hours to a maximum of four doses (24 hours)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Foley's Catheter</intervention_name>
    <description>intracervical extraamniotic Foley's catheter</description>
    <arm_group_label>group - 1 Foley's Catheter</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prostaglandin E1 analogue</intervention_name>
    <description>intravaginal misoprostol</description>
    <arm_group_label>Group - 2 Prostaglandin E1 Analogue</arm_group_label>
    <other_name>Misoprostol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Parturients who gave consent

          -  has low bishop score (≤5)

          -  term singleton cephalic presenting fetus

          -  intact membranes

          -  no contraindication to vaginal delivery

        Exclusion Criteria:

          -  those who refused consent

          -  preterm delivery

          -  vaginal infection

          -  non-cephalic presentation

          -  multiple gestation

          -  low lying placenta/previa,

          -  vaginal bleeding,

          -  previous cesarean section

          -  rupture of membranes
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nwali M Igwe</last_name>
    <phone>+2348036328316</phone>
    <email>matthewigwenwali@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Federal Teaching Hospital, Abakaliki</name>
      <address>
        <city>Abakaliki</city>
        <state>Ebonyi</state>
        <zip>480001</zip>
        <country>Nigeria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew I Nwali</last_name>
      <phone>+2348036328316</phone>
      <email>matthewigwenwali@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Nigeria</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2015</study_first_submitted>
  <study_first_submitted_qc>October 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2015</study_first_posted>
  <last_update_submitted>March 10, 2018</last_update_submitted>
  <last_update_submitted_qc>March 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Federal Teaching Hospital Abakaliki</investigator_affiliation>
    <investigator_full_name>Nwali Matthew Igwe</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
    <mesh_term>Alprostadil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

